NVS
Novartis AG trades as NVS and has a market capitalization of $294.66 B, making it the #46 largest US-listed company by market value. This page tracks Novartis AG through 981 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-04-30 |
| 6-K | - | 2026-04-28 |
| 6-K | - | 2026-03-18 |
| Prospectus supplement | 424B5 | 2026-03-17 |
| Free writing prospectus | FWP | 2026-03-17 |
| Prospectus supplement | 424B5 | 2026-03-16 |
| Insider sale notice | 144 | 2026-02-12 |
| Insider sale notice | 144 | 2026-02-09 |
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed · Net sales declined -5% (cc1, -1% USD), as growth drivers ...
Global \| **English**Novartis Foundation \| **English**(link is external)")
The largest companies sharing Novartis AG's SEC industry classification (pharmaceutical preparations).
Novartis AG (NVS) has a market capitalization of $294.66 B as of 2026-07-09, ranking #46 among US-listed companies.